Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study

ABP 501 is a biosimilar of adalimumab.

http://ift.tt/2neXDu3